Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer

Autor: Moll, Jan Matthijs, Teubel, Wilma J., Erkens, Sigrun E., Jozefzoon-Agai, Ashraf, Dits, Natasja F., van Rijswijk, Angelique, Jenster, Guido W., van Weerden, Wytske M.

Publikováno v: Frontiers in Oncology, 12:877613. Frontiers Media S.A.

Treatment of prostate cancer (PCa) has changed considerably in the last decade due to the introduction of novel androgen receptor (AR)-targeted agents (ARTAs) for patients progressing on androgen deprivation therapy (ADT). Preclinical research howeve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca571b3448cc3b49d6433f792f623cd
https://doi.org/10.3389/fonc.2022.877613

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.

Autor: Buck SAJ; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., Van Hemelryk A; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., de Ridder C; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., Stuurman D; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., Erkens-Schulze S; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., van 't Geloof S; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., Teubel WJ; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center Rotterdam, The Netherlands., Martens-Uzunova ES; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., van Royen ME; Department of Pathology, Erasmus University Medical Center Rotterdam, The Netherlands., de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands., van Weerden WM; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 May 02; Vol. 23 (5), pp. 711-720.